https://palatin.com/press_releases/palatin-announces-preliminary-fourth-quarter-fiscal-2023-vyleesi-product-revenue-results/ 2023-09-28T14:18:54+00:00 https://palatin.com/press_releases/palatin-to-participate-in-canaccord-genuitys-43rd-annual-growth-conference/ 2023-09-28T14:18:54+00:00 https://palatin.com/press_releases/palatin-announces-direct-to-consumer-telehealth-partnership-with-upscripthealth-for-vyleesi/ 2023-09-28T14:18:54+00:00 https://palatin.com/press_releases/palatins-vyleesi-licensee-fosun-pharma-reports-first-commercial-sale-in-china-and-south-korean-licensee-kwangdong-pharmaceuticals-completes-enrollment-in-phase-3-clinical-study/ 2023-09-28T14:18:54+00:00 https://palatin.com/press_releases/palatin-initiates-clinical-program-for-bremelanotide-co-formulated-with-a-pde5i-for-the-treatment-of-ed-in-patients-non-responsive-to-pde5i-treatment/ 2023-09-28T14:18:54+00:00 https://palatin.com/press_releases/palatin-completes-enrollment-in-phase-3-melody-1-study-of-pl9643-for-the-treatment-of-patients-with-dry-eye-disease/ 2023-09-28T14:18:54+00:00 https://palatin.com/press_releases/palatin-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference/ 2023-09-28T14:18:54+00:00 https://palatin.com/press_releases/palatin-to-report-fourth-quarter-and-fiscal-year-end-2023-results-teleconference-and-webcast-to-be-held-on-september-28-2023/ 2023-09-28T14:18:54+00:00 https://palatin.com/press_releases/palatin-reports-fourth-quarter-and-fiscal-year-ended-2023-financial-results-and-provides-corporate-update/ 2023-09-28T14:18:54+00:00 https://palatin.com/press_releases/palatin-announces-preliminary-second-quarter-fiscal-2023-vyleesi-product-sales-results/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/frontiers-in-immunology-publishes-pre-clinical-study-of-palatins-pl8177-demonstrating-therapeutic-effects-in-inflammatory-conditions/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-receives-4-7-million-of-non-dilutive-funding/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-initiates-enrollment-in-the-phase-2-bremelanotide-breakout-study-in-patients-with-diabetic-kidney-disease/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-to-report-second-quarter-fiscal-year-2023-results-teleconference-and-webcast-to-be-held-on-february-15-2023/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-reports-second-quarter-fiscal-year-2023-financial-results-and-provides-corporate-update/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-issued-patent-on-vyleesi-bremelanotide-injection-for-hypoactive-sexual-desire-disorder-in-patients-with-controlled-hypertension/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/frontiers-in-immunology-publishes-pre-clinical-study-of-palatins-oral-formulation-of-pl8177-demonstrating-therapeutic-effects-in-inflammatory-bowel-disease/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/pre-clinical-data-of-palatins-melanocortin-agonist-demonstrating-therapeutic-effects-in-diabetic-retinopathy-and-uveitis-published-in-the-international-journal-of-molecular-sciences/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-announces-preliminary-third-quarter-fiscal-2023-vyleesi-product-revenue-results/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-presents-data-at-the-association-of-research-in-vision-and-ophthalmology-2023-annual-conference-regarding-a-potential-treatment-for-glaucoma/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-presents-initial-dry-eye-disease-phase-3-clinical-data-at-the-association-of-research-in-vision-and-ophthalmology-2023-annual-conference/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-technologies-to-host-key-opinion-leader-webinar/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-invites-investors-to-listen-to-replay-of-the-pl9643-dry-eye-disease-key-opinion-leader-webinar/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-presents-pl8177-ulcerative-colitis-data-at-digestive-disease-week-annual-conference/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-to-report-third-quarter-fiscal-year-2023-results-teleconference-and-webcast-to-be-held-on-may-16-2023/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-reports-third-quarter-fiscal-year-2023-financial-results-and-provides-corporate-update/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-presents-preclinical-diabetic-nephropathy-data-at-the-international-podocyte-conference/ 2023-09-28T14:18:55+00:00 https://palatin.com/press_releases/palatin-announces-preliminary-fourth-quarter-vyleesi-net-product-revenue-increased-225-over-prior-quarter/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-reports-positive-interim-analysis-in-phase-3-pivotal-study-of-pl9643-in-patients-with-dry-eye-disease/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-announces-intent-to-effect-reverse-stock-split/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-announces-initiation-of-patient-recruitment-for-phase-2-clinical-study-evaluating-oral-pl8177-for-treatment-of-ulcerative-colitis/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-to-report-fourth-quarter-and-fiscal-year-end-2022-results-teleconference-and-webcast-to-be-held-on-september-22-2022/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-reports-fourth-quarter-and-fiscal-year-2022-financial-results-and-provides-corporate-update/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-to-participate-in-ladenburg-thalmann-healthcare-conference/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-announces-presentation-at-the-eyeceleratoraao-2022-conference/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-announces-preliminary-first-quarter-fiscal-2023-vyleesi-product-sales-results/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-announces-publication-of-vyleesi-bremelanotide-fmri-study-in-women-with-hypoactive-sexual-desire-disorder-hsdd/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/first-patient-enrolled-in-palatins-phase-2-study-of-pl8177-in-ulcerative-colitis-trial/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-presents-pl8177-data-at-american-college-of-gastroenterology-annual-meeting/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-announces-10-million-registered-direct-offering/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-to-report-first-quarter-fiscal-year-2023-results-teleconference-and-webcast-to-be-held-on-november-14-2022/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-reports-first-quarter-fiscal-year-2023-financial-results-and-provides-corporate-update/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-reports-third-quarter-fiscal-year-2022-financial-results-and-provides-corporate-update-2/ 2023-09-28T14:18:56+00:00 https://palatin.com/press_releases/palatin-to-present-at-eyecelerator-american-society-of-cataract-and-refractive-surgery-ascrs-2022-2/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-to-present-at-h-c-wainwright-bioconnect-conference-2/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-announces-initiation-of-pivotal-phase-3-pl9643-melody-1-clinical-trial-in-patients-with-dry-eye-disease-2/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-reports-first-quarter-fiscal-year-2022-results-and-provides-corporate-update-2/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-to-present-at-the-association-for-research-in-vision-and-ophthalmology-arvo-2022-annual-conference/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-announces-15-million-private-placement-of-convertible-redeemable-preferred-stock-2/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-to-report-third-quarter-fiscal-year-2022-results-teleconference-and-webcast-to-be-held-on-may-17-2022/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-to-report-second-quarter-fiscal-year-2022-results-teleconference-and-webcast-to-be-held-on-february-15-2022/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-announces-presentation-at-the-2022-crohns-and-colitis-congress/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-hosting-key-opinion-leader-webinar-on-dry-eye-disease-2/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-reports-second-quarter-fiscal-year-2022-financial-results-and-provides-corporate-update/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/notice-of-allowance-issued-for-method-of-treating-cytokine-storm-using-melanocortin-specific-peptide/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-awarded-top-10-poster-designation-at-the-american-society-of-retina-specialists-asrs-2021-annual-meeting/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-to-report-first-quarter-fiscal-year-2022-results-teleconference-and-webcast-to-be-held-on-november-15-2021/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-to-report-fourth-quarter-and-fiscal-year-end-2021-results-teleconference-and-webcast-to-be-held-on-september-29-2021/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-reports-fourth-quarter-and-full-year-fiscal-year-2021-financial-results-and-provides-corporate-update/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-announces-presentation-of-positive-protective-effects-of-pl8331-and-pl9654-on-retinal-inflammation-at-the-2021-american-society-of-retina-specialists-asrs-annual-meeting/ 2023-09-28T14:18:57+00:00 https://palatin.com/press_releases/palatin-announces-presentation-at-the-eyeceleratorascrs-conference/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-announces-adjournment-of-annual-meeting-of-stockholders/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-announces-new-additions-to-its-senior-leadership-team/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-to-participate-in-h-c-wainwright-23rd-annual-global-investment-virtual-conference-2/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-announces-positive-end-of-phase-2-meeting-with-fda-on-pl9643-for-the-treatment-of-dry-eye-disease-2/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-announces-adjournment-of-annual-meeting-of-stockholders-4/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-quarter-fiscal-year-2021-financial-results-and-recent-business-highlights-2/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2021-results-teleconference-and-webcast-to-be-held-on-february-17-2021-2/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-announces-two-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting-2/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-technologies-to-participate-in-h-c-wainwright-global-life-sciences-virtual-conference-2/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-technologies-announces-filing-of-international-patent-application-claiming-pl9643-2/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-announces-u-s-patent-term-extension-for-vyleesi-bremelanotide-injection-2/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-to-report-third-quarter-fiscal-year-2021-results-teleconference-and-webcast-to-be-held-on-may-17-2021-2/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-reports-financial-results-for-the-third-fiscal-quarter-of-2021-and-provides-corporate-update-2/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-hosting-key-opinion-leader-webinar-in-role-of-melanocortin-agonists-in-inflammation-and-the-treatment-of-ocular-indications-2/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-to-present-peptides-platform-at-the-tides-usa-conference/ 2023-09-28T14:18:58+00:00 https://palatin.com/press_releases/palatin-technologies-announces-positive-results-from-its-phase-2-study-of-pl9643-in-patients-with-dry-eye-disease-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2021-results-teleconference-and-webcast-to-be-held-on-november-17-2020-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-first-quarter-fiscal-year-2021-results-and-provides-business-update-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-fourth-quarter-and-fiscal-year-2020-financial-results-and-provides-a-business-update-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-the-h-c-wainwright-co-22nd-annual-global-investment-conference-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fourth-quarter-and-fiscal-year-end-2020-results-teleconference-and-webcast-to-be-held-on-september-28-2020-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-announces-mutual-termination-of-license-agreement-with-amag-pharmaceuticals-for-vyleesi-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-participates-in-canaccord-genuitys-40th-annual-growth-conference-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-reinitiation-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-completion-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-to-develop-pl8177-as-a-potential-treatment-for-covid-19-and-associated-lung-complications-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-announces-adjournment-of-annual-meeting-of-stockholders-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2020-results-teleconference-and-webcast-to-be-held-on-may-12-2020-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-third-quarter-fiscal-year-2020-financial-results-and-recent-business-highlights-2/ 2023-09-28T14:18:59+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-quarter-fiscal-year-2020-financial-results-and-recent-business-highlights/ 2023-09-28T14:19:00+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-first-quarter-fiscal-year-2020-results-and-provides-corporate-update/ 2023-09-28T14:19:00+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-first-patient-enrolled-in-dry-eye-disease-phase-2-clinical-trial-with-pl9643-2/ 2023-09-28T14:19:00+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2020-results-teleconference-and-webcast-to-be-held-on-february-11-2020-2/ 2023-09-28T14:19:00+00:00 https://palatin.com/press_releases/palatin-provides-corporate-update-and-2020-calendar-outlook-2/ 2023-09-28T14:19:00+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2020-results-teleconference-and-webcast-to-be-held-on-november-13-2019-2/ 2023-09-28T14:19:00+00:00 https://palatin.com/press_releases/vyleesi-phase-3-data-to-be-presented-at-the-13th-european-society-of-gynecology-congress-2/ 2023-09-28T14:19:00+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-2019-results-2/ 2023-09-28T14:19:00+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fourth-quarter-teleconference-and-webcast-to-be-held-on-september-12-2019-2/ 2023-09-28T14:19:00+00:00 https://palatin.com/press_releases/palatin-technologies-provides-assessment-of-impact-of-covid-19-pandemic-on-business-operations/ 2023-09-28T14:19:00+00:00 https://palatin.com/press_releases/palatin-presents-on-pl8177-oral-colon-delivery-formulation-for-ulcerative-colitis-at-the-7th-cpc-symposium-on-peptide-therapeutics/ 2023-09-28T14:19:00+00:00 https://palatin.com/press_releases/palatin-technologies-provides-mid-calendar-year-corporate-update/ 2023-09-28T14:19:01+00:00 https://palatin.com/press_releases/palatin-technologies-granted-fda-orphan-drug-designation-pl-8177-for-the-treatment-of-non-infectious-uveitis/ 2023-09-28T14:19:01+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-fiscal-quarter-2019-results-and-provides-corporate-update/ 2023-09-28T14:19:01+00:00 https://palatin.com/press_releases/fda-approves-new-drug-application-for-vyleesi-bremelanotide-injection-2/ 2023-09-28T14:19:01+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-canaccord-genuitys-39th-annual-growth-conference-2/ 2023-09-28T14:19:01+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-third-quarter-fiscal-year-2019-results-teleconference-and-webcast-to-be-held-on-may-9-2019-2/ 2023-09-28T14:19:01+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2019-results-teleconference-and-webcast-to-be-held-on-may-9-2019-2/ 2023-09-28T14:19:01+00:00 https://palatin.com/press_releases/palatin-technologies-announces-positive-top-line-results-of-oral-clinical-study-of-pl-8177-for-ulcerative-colitis-and-other-inflammatory-bowel-diseases-2/ 2023-09-28T14:19:01+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2019-results-teleconference-and-webcast-to-be-held-on-february-12-2019/ 2023-09-28T14:19:01+00:00 https://palatin.com/press_releases/palatin-technologies-announces-fda-acceptance-for-review-of-bremelanotide-nda/ 2023-09-28T14:19:02+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-first-fiscal-quarter-2019-results-and-provides-corporate-update/ 2023-09-28T14:19:02+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-first-in-human-study-results-of-subcutaneous-administration-of-pl-8177-an-investigational-melanocortin-receptor-1-agonist-2/ 2023-09-28T14:19:02+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2019-results-teleconference-and-webcast-to-be-held-on-november-13-2018-2/ 2023-09-28T14:19:02+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fourth-quarter-and-fiscal-year-end-2018-results-teleconference-and-webcast-to-be-held-on-september-13-2018-2/ 2023-09-28T14:19:02+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-third-quarter-fiscal-year-2018-results-teleconference-and-webcast-to-be-held-on-may-15-2018-2/ 2023-09-28T14:19:02+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2018-results-teleconference-and-webcast-to-be-held-on-may-15-2018-2/ 2023-09-28T14:19:02+00:00 https://palatin.com/press_releases/palatin-technologies-added-to-russell-3000-index-2/ 2023-09-28T14:19:02+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-2018-results/ 2023-09-28T14:19:02+00:00 https://palatin.com/press_releases/palatin-technologies-presents-positive-preclinical-mc1-receptor-agonist-data-at-tides-oligonucleotide-and-peptide-therapeutics-2018-meeting-in-boston-massachusetts/ 2023-09-28T14:19:03+00:00 https://palatin.com/press_releases/palatin-technologies-presents-preclinical-oral-formulation-data-on-pl-8177-an-investigational-melanocortin-receptor-1-agonist-for-inflammatory-bowel-diseases/ 2023-09-28T14:19:03+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-quarter-fiscal-year-2018-results-teleconference-and-webcast-to-be-held-on-february-12-2018-2/ 2023-09-28T14:19:03+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2018-results-teleconference-and-webcast-to-be-held-on-february-12-2018-2/ 2023-09-28T14:19:03+00:00 https://palatin.com/press_releases/palatin-technologies-announces-signing-of-licensing-agreement-with-kwangdong-pharmaceutical-for-republic-of-korea-2/ 2023-09-28T14:19:03+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-fda-clearance-of-investigational-new-drug-ind-application-for-pl-8177-for-ulcerative-colitis/ 2023-09-28T14:19:03+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-first-quarter-fiscal-year-2018-results-teleconference-and-webcast-to-be-held-on-november-13-2017/ 2023-09-28T14:19:03+00:00 https://palatin.com/press_releases/palatin-technologies-inc-initiates-subject-dosing-in-first-in-human-clinical-study-of-pl-8177-an-investigational-melanocortin-receptor-1-agonist/ 2023-09-28T14:19:03+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fourth-quarter-and-fiscal-year-end-2017-results-teleconference-and-webcast-to-be-held-on-september-25-2017/ 2023-09-28T14:19:04+00:00 https://palatin.com/press_releases/palatin-technologies-receives-notice-of-allowance-on-bremelanotide-methods-of-use-patent-for-treatment-of-hypoactive-sexual-desire-disorder-in-premenopausal-women/ 2023-09-28T14:19:04+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2018-results-teleconference-and-webcast-to-be-held-on-november-13-2017/ 2023-09-28T14:19:04+00:00 https://palatin.com/press_releases/palatin-technologies-announces-signing-of-licensing-agreement-with-fosun-pharma-rights-to-bremelanotide-in-china-and-other-selected-territories/ 2023-09-28T14:19:04+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-2017-results-teleconference-and-webcast-to-be-held-on-september-25-2017/ 2023-09-28T14:19:04+00:00 https://palatin.com/press_releases/palatin-technologies-announces-appointment-of-anthony-m-manning-ph-d-to-board-of-directors-2/ 2023-09-28T14:19:04+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-third-quarter-fiscal-year-2017-results-teleconference-and-webcast-to-be-held-on-may-16-2017-2/ 2023-09-28T14:19:04+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2017-results-teleconference-and-webcast-to-be-held-on-may-16-2017-2/ 2023-09-28T14:19:04+00:00 https://palatin.com/press_releases/palatin-technologies-to-hold-call-following-closing-of-licensing-agreement-for-north-american-rights-to-rekynda/ 2023-09-28T14:19:05+00:00 https://palatin.com/press_releases/palatin-technologies-closes-on-16-5-million-financing/ 2023-09-28T14:19:05+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-quarter-fiscal-year-2017-results-teleconference-and-webcast-to-be-held-on-february-9-2017/ 2023-09-28T14:19:05+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-the-29th-annual-roth-conference-2/ 2023-09-28T14:19:05+00:00 https://palatin.com/press_releases/palatin-technologies-announces-closing-of-license-agreement-with-amag-pharmaceuticals-for-north-american-rights-to-rekynda-2/ 2023-09-28T14:19:05+00:00 https://palatin.com/press_releases/palatin-technologies-announces-pricing-of-public-offering-of-common-stock-and-warrants-2/ 2023-09-28T14:19:05+00:00 https://palatin.com/press_releases/palatin-technologies-announces-proposed-public-offering-of-common-stock-and-warrants-2/ 2023-09-28T14:19:05+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-first-quarter-fiscal-year-2017-results-teleconference-and-webcast-to-be-held-on-november-15-2016-2/ 2023-09-28T14:19:05+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2017-results-teleconference-and-webcast-to-be-held-on-november-15-2016/ 2023-09-28T14:19:06+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-the-36th-annual-canaccord-genuity-growth-conference/ 2023-09-28T14:19:06+00:00 https://palatin.com/press_releases/palatin-technologies-announces-completion-of-all-patient-visits-in-phase-3-clinical-trials-of-bremelanotide-for-hypoactive-sexual-desire-disorder/ 2023-09-28T14:19:06+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-2016-results/ 2023-09-28T14:19:06+00:00 https://palatin.com/press_releases/palatin-technologies-receives-audit-opinion-with-going-concern-explanation/ 2023-09-28T14:19:06+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fourth-quarter-fiscal-year-end-2016-results-teleconference-and-webcast-to-be-held-on-september-20-2016/ 2023-09-28T14:19:06+00:00 https://palatin.com/press_releases/palatin-technologies-presents-bremelanotide-neurobiology-and-treatment-efficacy-review-at-world-meeting-on-sexual-medicine/ 2023-09-28T14:19:06+00:00 https://palatin.com/press_releases/palatin-technologies-announces-9-25-million-financing/ 2023-09-28T14:19:07+00:00 https://palatin.com/press_releases/palatin-technologies-receives-patent-strengthening-its-melanocortin-peptide-intellectual-property/ 2023-09-28T14:19:07+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2016-results/ 2023-09-28T14:19:07+00:00 https://palatin.com/press_releases/palatin-technologies-announces-closing-of-9-2-million-financing/ 2023-09-28T14:19:07+00:00 https://palatin.com/press_releases/palatin-technologies-receives-patent-strengthening-its-melanocortin-peptide-intellectual-property-2/ 2023-09-28T14:19:07+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-third-quarter-fiscal-year-2016-results-teleconference-and-webcast-to-be-held-on-may-17-2016/ 2023-09-28T14:19:07+00:00 https://palatin.com/press_releases/palatin-technologies-presents-bremelanotide-alcohol-interaction-study-at-international-society-for-the-study-of-womens-sexual-health-annual-meeting/ 2023-09-28T14:19:07+00:00 https://palatin.com/press_releases/palatin-technologies-strengthens-intellectual-property-surrounding-use-of-bremelanotide-for-female-sexual-dysfunction/ 2023-09-28T14:19:08+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2016-results/ 2023-09-28T14:19:08+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-quarter-fiscal-year-2016-results-teleconference-and-webcast-to-be-held-on-february-16-2016/ 2023-09-28T14:19:08+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-the-bio-ceo-investor-conference-2/ 2023-09-28T14:19:08+00:00 https://palatin.com/press_releases/palatin-technologies-achieves-target-patient-enrollment-in-pivotal-phase-3-studies-for-bremelanotide-for-female-sexual-dysfunction/ 2023-09-28T14:19:08+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2016-results-teleconference-and-webcast-to-be-held-on-november-12-2015/ 2023-09-28T14:19:09+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-end-2015-results/ 2023-09-28T14:19:09+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-first-quarter-fiscal-year-2016-results-teleconference-and-webcast-to-be-held-on-november-12-2015/ 2023-09-28T14:19:09+00:00 https://palatin.com/press_releases/palatin-technologies-and-richter-terminate-license-agreement-for-bremelanotide-for-female-sexual-dysfunction/ 2023-09-28T14:19:09+00:00 https://palatin.com/press_releases/preclinical-data-on-pl-3994-for-heart-failure-and-resistant-hypertension-presented-at-2015-heart-failure-society-of-america-annual-meeting/ 2023-09-28T14:19:09+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fourth-quarter-fiscal-year-end-2015-results/ 2023-09-28T14:19:10+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-third-quarter-fiscal-year-2015-results-teleconference-and-webcast-to-be-held-on-may-13-2015/ 2023-09-28T14:19:10+00:00 https://palatin.com/press_releases/palatin-technologies-supports-fdas-approval-of-the-first-ever-treatment-for-female-sexual-dysfunction/ 2023-09-28T14:19:10+00:00 https://palatin.com/press_releases/palatin-technologies-completes-30-million-financing/ 2023-09-28T14:19:10+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2015-results/ 2023-09-28T14:19:10+00:00 https://palatin.com/press_releases/palatin-supports-fda-advisory-committees-recommendation-to-approve-the-first-ever-treatment-for-hypoactive-sexual-desire-disorder/ 2023-09-28T14:19:10+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-the-bio-ceo-investor-conference/ 2023-09-28T14:19:11+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-quarter-fiscal-year-2015-results-teleconference-and-webcast-to-be-held-on-february-13-2015/ 2023-09-28T14:19:11+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2015-results-teleconference-and-webcast-to-be-held-on-february-13-2015/ 2023-09-28T14:19:11+00:00 https://palatin.com/press_releases/palatin-launches-reconnectstudy-com-in-support-of-bremelanotide-phase-3-program-for-female-sexual-dysfunction/ 2023-09-28T14:19:11+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-the-27th-annual-roth-conference/ 2023-09-28T14:19:11+00:00 https://palatin.com/press_releases/palatin-completes-20-million-equity-and-10-million-debt-financings/ 2023-09-28T14:19:12+00:00 https://palatin.com/press_releases/palatin-announces-start-of-bremelanotide-phase-3-program-for-female-sexual-dysfunction/ 2023-09-28T14:19:12+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-first-quarter-fiscal-year-2015-results-teleconference-and-webcast-to-be-held-on-november-18-2014/ 2023-09-28T14:19:12+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2015-results/ 2023-09-28T14:19:12+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-end-2014-results/ 2023-09-28T14:19:13+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-the-13th-annual-bio-investor-forum/ 2023-09-28T14:19:13+00:00 https://palatin.com/press_releases/survey-reveals-low-sexual-desire-disrupts-relationships/ 2023-09-28T14:19:13+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fourth-quarter-and-fiscal-year-2014-results/ 2023-09-28T14:19:14+00:00 https://palatin.com/press_releases/palatin-technologies-licenses-bremelanotide-in-europe-and-other-selected-countries-to-richter/ 2023-09-28T14:19:14+00:00 https://palatin.com/press_releases/palatin-technologies-announces-notification-of-patent-allowance-on-melanocortin-receptor-1-specific-peptides/ 2023-09-28T14:19:15+00:00 https://palatin.com/press_releases/palatin-technologies-to-join-russell-microcap-index/ 2023-09-28T14:19:15+00:00 https://palatin.com/press_releases/palatin-technologies-announces-notification-of-patent-allowance-on-next-generation-melanocortin-receptor-specific-peptides/ 2023-09-28T14:19:16+00:00 https://palatin.com/press_releases/new-survey-reveals-that-low-sexual-desire-disrupts-relationships/ 2023-09-28T14:19:16+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-third-quarter-fiscal-year-2014-results/ 2023-09-28T14:19:17+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-third-quarter-fiscal-year-2014-results-teleconference-and-webcast-to-be-held-on-may-13-2014/ 2023-09-28T14:19:17+00:00 https://palatin.com/press_releases/palatin-technologies-announces-option-extension-for-license-to-bremelanotide-in-europe/ 2023-09-28T14:19:18+00:00 https://palatin.com/press_releases/palatin-technologies-presents-at-the-annual-clinical-meeting-of-the-american-college-of-obstetricians-and-gynecologists-acog/ 2023-09-28T14:19:18+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-quarter-fiscal-year-2014-results-teleconference-and-webcast-to-be-held-on-february-18-2014/ 2023-09-28T14:19:19+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-the-26th-annual-roth-conference/ 2023-09-28T14:19:19+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-second-quarter-fiscal-year-2014-results/ 2023-09-28T14:19:20+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-the-16th-congress-of-the-european-society-for-sexual-medicine/ 2023-09-28T14:19:20+00:00 https://palatin.com/press_releases/palatin-technologies-responds-to-unusual-market-activity/ 2023-09-28T14:19:21+00:00 https://palatin.com/press_releases/palatin-technologies-inc-receives-1-85-million-from-sale-of-new-jersey-state-tax-credits/ 2023-09-28T14:19:21+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-first-quarter-fiscal-year-2014-results-teleconference-and-webcast-to-be-held-on-november-14-2013/ 2023-09-28T14:19:22+00:00 https://palatin.com/press_releases/palatin-technologies-to-participate-in-the-25th-annual-piper-jaffray-healthcare-conference/ 2023-09-28T14:19:22+00:00 https://palatin.com/press_releases/palatin-technologies-announces-issuance-of-two-natriuretic-peptide-receptor-specific-mimetic-patents/ 2023-09-28T14:19:23+00:00 https://palatin.com/press_releases/palatin-technologies-announces-option-for-license-to-bremelanotide-in-europe/ 2023-09-28T14:19:23+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2014-results-teleconference-and-webcast-to-be-held-on-november-14-2013/ 2023-09-28T14:19:24+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-the-12th-annual-bio-investor-forum/ 2023-09-28T14:19:25+00:00 https://palatin.com/press_releases/palatin-technologies-reports-successful-completion-of-device-bioequivalence-trial/ 2023-09-28T14:19:25+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2013-fourth-quarter-results/ 2023-09-28T14:19:26+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2013-third-quarter-results-teleconference-and-webcast-to-be-held-on-may-14-2013/ 2023-09-28T14:19:27+00:00 https://palatin.com/press_releases/palatin-technologies-announces-third-quarter-fiscal-year-2013-results-and-update-on-development-of-bremelanotide-for-female-sexual-dysfunction/ 2023-09-28T14:19:27+00:00 https://palatin.com/press_releases/palatin-technologies-announces-notification-of-patent-allowance-on-melanocortin-receptor-specific-peptides-for-sexual-dysfunction/ 2023-09-28T14:19:28+00:00 https://palatin.com/press_releases/palatin-technologies-announces-notification-of-patent-allowance-on-melanocortin-receptor-1-specific-peptides-2/ 2023-09-28T14:19:29+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-the-25th-annual-roth-conference/ 2023-09-28T14:19:29+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-quarter-fiscal-year-2013-results-teleconference-and-webcast-to-be-held-on-february-14-2013/ 2023-09-28T14:19:30+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2013-second-quarter-results-teleconference-and-webcast-to-be-held-on-february-14-2013/ 2023-09-28T14:19:31+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-present-at-15th-annual-bio-ceo-investor-conference/ 2023-09-28T14:19:31+00:00 https://palatin.com/press_releases/palatin-technologies-receives-1-75-million-from-sale-of-new-jersey-state-tax-credits/ 2023-09-28T14:19:32+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-present-at-the-24th-annual-piper-jaffray-healthcare-conference/ 2023-09-28T14:19:33+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-first-quarter-fiscal-year-2013-results-teleconference-and-webcast-to-be-held-on-november-14-2012/ 2023-09-28T14:19:33+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-present-at-the-lazard-capital-markets-9th-annual-healthcare-conference/ 2023-09-28T14:19:34+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2013-first-quarter-results-teleconference-and-webcast-to-be-held-on-november-14-2012/ 2023-09-28T14:19:35+00:00 https://palatin.com/press_releases/palatin-technologies-reports-positive-results-for-phase-2b-bremelanotide-female-sexual-dysfunction-trial/ 2023-09-28T14:19:36+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-end-2012-results/ 2023-09-28T14:19:36+00:00 https://palatin.com/press_releases/palatin-technologies-announces-last-patient-completed-treatment-in-phase-2b-bremelanotide-female-sexual-dysfunction-trial/ 2023-09-28T14:19:37+00:00 https://palatin.com/press_releases/palatin-technologies-provides-update-regarding-its-obesity-research-development-collaboration-with-astrazeneca/ 2023-09-28T14:19:38+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2012-fourth-quarter-results-teleconference-and-webcast-to-be-held-on-september-11-2012/ 2023-09-28T14:19:39+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-pricing-of-35-million-private-placement-of-common-stock-and-warrants/ 2023-09-28T14:19:40+00:00 https://palatin.com/press_releases/palatin-technologies-announces-halting-of-phase-i-clinical-trial-of-obesity-compound-in-astrazeneca-research-collaboration/ 2023-09-28T14:19:41+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-third-quarter-fiscal-year-2012-results-teleconference-and-webcast-to-be-held-on-may-14-2012/ 2023-09-28T14:19:41+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2012-third-quarter-results-teleconference-and-webcast-to-be-held-on-may-14-2012/ 2023-09-28T14:19:42+00:00 https://palatin.com/press_releases/palatin-technologies-completes-enrollment-in-phase-2b-bremelanotide-female-sexual-dysfunction-trial/ 2023-09-28T14:19:43+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-present-at-the-24th-annual-roth-oc-growth-stock-conference/ 2023-09-28T14:19:44+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-quarter-fiscal-year-2012-results-teleconference-and-webcast-to-be-held-on-february-15-2012/ 2023-09-28T14:19:45+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-14th-annual-bio-ceo-investor-conference/ 2023-09-28T14:19:46+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2012-second-quarter-results-teleconference-and-webcast-to-be-held-on-february-15-2012/ 2023-09-28T14:19:47+00:00 https://palatin.com/press_releases/palatin-technologies-receives-1-1-million-from-sale-of-new-jersey-state-tax-credits/ 2023-09-28T14:19:48+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-bocemb-noble-financial-capital-markets-eighth-annual-equity-conference/ 2023-09-28T14:19:49+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-windhovers-therapeutic-area-partnerships-conference/ 2023-09-28T14:19:50+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2012-first-quarter-results-teleconference-and-webcast-to-be-held-on-november-15-2011/ 2023-09-28T14:19:51+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-end-2011-results/ 2023-09-28T14:19:52+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2011-fourth-quarter-results-teleconference-and-webcast-to-be-held-on-september-22-2011/ 2023-09-28T14:19:53+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-present-at-the-rodman-renshaw-annual-global-investment-conference/ 2023-09-28T14:19:54+00:00 https://palatin.com/press_releases/palatin-announces-commencement-of-a-phase-1-trial-for-obesity-compound-in-collaboration-with-astrazeneca/ 2023-09-28T14:19:55+00:00 https://palatin.com/press_releases/alan-dunton-m-d-joins-board-of-directors-of-palatin-technologies-inc/ 2023-09-28T14:19:56+00:00 https://palatin.com/press_releases/palatin-technologies-inc-issued-u-s-patent-for-key-component-in-pl-3994-drug-candidate/ 2023-09-28T14:19:57+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-presentation-and-publication-on-validation-of-scale-for-subjective-male-sexual-arousal/ 2023-09-28T14:19:58+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-third-quarter-fiscal-year-2011-results/ 2023-09-28T14:19:59+00:00 https://palatin.com/press_releases/palatin-technologies-inc-march-31-2011-quarter-results-teleconference-and-webcast-to-be-held-on-may-16-2011/ 2023-09-28T14:20:00+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-results-of-annual-stockholders-meeting/ 2023-09-28T14:20:09+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-present-at-the-roth-23rd-annual-oc-growth-stock-conference/ 2023-09-28T14:20:12+00:00 https://palatin.com/press_releases/fda-clears-palatin-technologies-ind-filing-to-commence-clinical-studies-for-asthma/ 2023-09-28T14:20:14+00:00 https://palatin.com/press_releases/palatin-technologies-inc-closes-23-million-public-offering/ 2023-09-28T14:20:15+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-pricing-of-public-offering-of-common-stock-and-warrants/ 2023-09-28T14:20:17+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-proposed-public-offering-of-common-stock-and-warrants/ 2023-09-28T14:20:18+00:00 https://palatin.com/press_releases/palatin-technologies-inc-december-31-2010-quarter-results-teleconference-and-webcast-to-be-held-on-february-24-2011/ 2023-09-28T14:20:20+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-quarter-fiscal-year-2011-results/ 2023-09-28T14:20:21+00:00 https://palatin.com/press_releases/palatin-technologies-listing-compliance-plan-accepted-by-nyse-amex/ 2023-09-28T14:20:22+00:00 https://palatin.com/press_releases/palatin-technologies-receives-non-compliance-letter-from-nyse-amex/ 2023-09-28T14:20:23+00:00 https://palatin.com/press_releases/palatin-technologies-appoints-jeffrey-d-edelson-m-d-chief-medical-officer/ 2023-09-28T14:20:25+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-first-quarter-fiscal-year-2011-results-teleconference-and-webcast-to-be-held-on-november-16-2010/ 2023-09-28T14:20:26+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2011-first-quarter-results-teleconference-and-webcast-to-be-held-on-november-16-2010/ 2023-09-28T14:20:27+00:00 https://palatin.com/press_releases/palatin-technologies-inc-receives-978000-in-grants-under-the-patient-protection-and-affordable-care-program/ 2023-09-28T14:20:29+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-9th-annual-bio-investor-forum/ 2023-09-28T14:20:30+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-end-2010-results-teleconference-and-webcast-to-be-held-on-september-27-2010/ 2023-09-28T14:20:32+00:00 https://palatin.com/press_releases/palatin-announces-strategic-realignment-of-operations/ 2023-09-28T14:20:34+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2010-fourth-quarter-results-teleconference-and-webcast-to-be-held-on-september-27-2010/ 2023-09-28T14:20:35+00:00 https://palatin.com/press_releases/palatin-technologies-to-present-at-rodman-renshaw-annual-global-investment-conference/ 2023-09-28T14:20:37+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-positive-safety-results-in-subcutaneous-bremelanotide-trial-in-men/ 2023-09-28T14:20:38+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-last-patient-dosed-and-database-lock-in-subcutaneous-bremelanotide-trial-in-men/ 2023-09-28T14:20:40+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-positive-preclinical-data-with-pl-3994-for-asthma-indications/ 2023-09-28T14:20:42+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-third-quarter-fiscal-year-2010-results-teleconference-and-webcast-to-be-held-on-may-13-2010/ 2023-09-28T14:20:44+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-report-fiscal-year-2010-third-quarter-results-teleconference-and-webcast-to-be-held-on-may-13-2010/ 2023-09-28T14:20:46+00:00 https://palatin.com/press_releases/palatin-technologies-inc-issued-u-s-patent-and-receives-patent-allowance-on-seven-additional-patents/ 2023-09-28T14:20:48+00:00 https://palatin.com/press_releases/palatin-technologies-inc-receives-2-5-million-from-astrazeneca/ 2023-09-28T14:20:50+00:00 https://palatin.com/press_releases/palatin-technologies-inc-to-raise-2-6-million-dollars-in-registered-direct-offering/ 2023-09-28T14:20:52+00:00 https://palatin.com/press_releases/palatin-technologies-inc-reports-second-quarter-fiscal-year-2010-results-teleconference-and-webcast-to-be-held-on-february-16-2010/ 2023-09-28T14:20:53+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-dosing-of-subcutaneous-bremelanotide-trial-in-men/ 2023-09-28T14:20:55+00:00 https://palatin.com/press_releases/test/ 2023-09-28T14:20:57+00:00 https://palatin.com/press_releases/palatin-receives-notice-of-non-compliance-from-nyse-american/ 2023-10-16T13:58:20+00:00 https://palatin.com/press_releases/palatin-presents-data-at-the-united-european-gastroenterology-week-2023-conference-on-pl8177-ulcerative-colitis-treatment/ 2023-10-16T13:59:23+00:00 https://palatin.com/press_releases/palatin-announces-preliminary-quarter-ended-september-30-2023-vyleesi-product-revenue-results/ 2023-10-19T10:15:34+00:00 https://palatin.com/press_releases/palatin-announces-positive-preclinical-data-showing-synergistic-weight-loss-initiating-clinical-study-of-melanocortin-4-receptor-agonist-glp-1-in-obese-patients/ 2023-10-19T10:16:08+00:00 https://palatin.com/press_releases/palatin-announces-5-million-registered-direct-offering/ 2023-10-23T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-closing-of-5-million-registered-direct-offering/ 2023-10-24T16:50:00+00:00 https://palatin.com/press_releases/palatin-to-report-first-quarter-fiscal-year-2024-results-teleconference-and-webcast-to-be-held-on-november-14-2023/ 2023-11-09T07:30:00+00:00 https://palatin.com/press_releases/palatin-reports-first-quarter-fiscal-year-2024-financial-results-and-provides-corporate-update/ 2023-11-14T07:30:00+00:00 https://palatin.com/press_releases/palatin-receives-notice-of-acceptance-of-the-listing-standards-compliance-plan-from-nyse-american/ 2023-12-18T16:15:00+00:00 https://palatin.com/press_releases/palatin-completes-sale-of-vyleesi-to-cosette-pharmaceuticals-for-up-to-171-million/ 2023-12-20T07:30:00+00:00 https://palatin.com/press_releases/palatin-provides-corporate-update-and-highlights-strategic-priorities-for-calendar-year-2024/ 2024-01-08T10:33:00+00:00 https://palatin.com/press_releases/palatin-announces-10-million-registered-direct-offering-2/ 2024-01-30T08:00:00+00:00 https://palatin.com/press_releases/palatin-announces-closing-of-10-million-registered-direct-offering/ 2024-02-01T16:00:00+00:00 https://palatin.com/press_releases/palatin-announces-database-lock-for-pl9643-melody-1-pivotal-phase-3-clinical-trial-in-patients-with-dry-eye-disease-ded/ 2024-02-05T07:30:00+00:00 https://palatin.com/press_releases/palatin-to-report-second-quarter-fiscal-year-2024-results-teleconference-and-webcast-to-be-held-on-february-15-2024/ 2024-02-09T07:30:00+00:00 https://palatin.com/press_releases/palatin-reports-second-quarter-fiscal-year-2024-financial-results-and-provides-corporate-update/ 2024-02-15T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-results-of-pl9643-melody-1-pivotal-phase-3-clinical-trial-in-patients-with-dry-eye-disease-ded/ 2024-02-28T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-phase-3-pl9643-melody-1-dry-eye-disease-ded-clinical-data-results-presented-at-american-society-of-cataract-and-refractive-surgery-ascrs-2024/ 2024-04-08T07:30:00+00:00 https://palatin.com/press_releases/palatin-to-host-virtual-kol-event-beyond-glps-the-multiple-roles-for-novel-melanocortin-receptor-4-agonists-in-treating-obesity-and-weight-loss-maintenance-on-may-8-2024/ 2024-04-30T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-fda-clearance-of-ind-application-for-the-co-administration-of-bremelanotide-with-tirzepatide-glp-1-for-the-treatment-of-obesity/ 2024-05-02T07:30:00+00:00 https://palatin.com/press_releases/palatin-to-report-third-quarter-fiscal-year-2024-results-teleconference-and-webcast-to-be-held-on-may-15-2024/ 2024-05-09T07:30:00+00:00 https://palatin.com/press_releases/palatin-reports-third-quarter-fiscal-year-2024-financial-results-and-provides-corporate-update/ 2024-05-15T07:30:00+00:00 https://palatin.com/press_releases/palatin-initiates-phase-2-clinical-study-of-bremelanotide-for-the-treatment-of-obesity/ 2024-06-12T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-the-initiation-of-a-phase-2-clinical-study-of-bremelanotide-co-administered-with-a-pde5i-for-the-treatment-of-erectile-dysfunction-ed/ 2024-06-20T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-exercise-of-warrants-for-approximately-6-1-million-gross-proceeds/ 2024-06-21T08:00:00+00:00 https://palatin.com/press_releases/first-patient-dosed-in-phase-2-clinical-study-of-palatins-bremelanotide-co-administered-with-tirzepatide-glp-1-for-the-treatment-of-obesity/ 2024-08-22T07:30:00+00:00 https://palatin.com/press_releases/fda-confirms-acceptability-of-palatins-remaining-phase-3-pivotal-clinical-trials-for-pl9643-in-dry-eye-disease-ded/ 2024-08-28T07:30:00+00:00 https://palatin.com/press_releases/palatin-provides-update-on-clinical-programs-strategic-priorities-and-anticipated-milestones/ 2024-09-09T07:30:00+00:00 https://palatin.com/press_releases/palatin-to-report-fourth-quarter-and-fiscal-year-end-2024-results/ 2024-09-26T07:30:00+00:00 https://palatin.com/press_releases/palatin-reports-fourth-quarter-and-fiscal-year-ended-2024-financial-results-provides-update-on-clinical-programs-strategic-priorities-and-anticipated-milestones/ 2024-10-01T07:30:00+00:00 https://palatin.com/press_releases/palatin-receives-notice-of-non-compliance-from-nyse-american-2/ 2024-10-07T16:15:00+00:00 https://palatin.com/press_releases/palatin-presents-foundational-data-on-novel-and-highly-selective-melanocortin-4-receptor-agonists-at-the-19th-annual-peptide-therapeutics-symposium/ 2024-10-23T07:30:00+00:00 https://palatin.com/press_releases/inflammatory-disease-healing-data-via-palatins-novel-melanocortin-receptor-agonists-presented-at-the-19th-annual-peptide-therapeutics-symposium/ 2024-10-24T07:30:00+00:00 https://palatin.com/press_releases/palatin-completes-enrollment-in-phase-2-clinical-study-of-bremelanotide-mc4r-agonist-co-administered-with-tirzepatide-glp-1-gip-for-the-treatment-of-obesity/ 2024-10-31T07:30:00+00:00 https://palatin.com/press_releases/palatin-presents-data-on-novel-melanocortin-4-receptor-selective-oral-small-molecule-pl7737-obesity-program-at-obesityweek-2024/ 2024-11-04T07:30:00+00:00 https://palatin.com/press_releases/palatin-to-report-first-quarter-fiscal-year-2025-results-teleconference-and-webcast-to-be-held-on-november-14-2024/ 2024-11-08T09:57:00+00:00 https://palatin.com/press_releases/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results/ 2024-11-14T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-completion-of-patient-enrollment-in-phase-2-study-of-orally-administered-melanocortin-agonist-pl8177-in-ulcerative-colitis/ 2024-11-25T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-exercise-of-warrants-for-approximately-3-4-million-gross-proceeds/ 2024-12-16T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-positive-phase-iib-breakout-study-results-in-patients-with-type-2-diabetic-nephropathy/ 2024-12-19T07:30:00+00:00 https://palatin.com/press_releases/palatin-provides-update-on-anticipated-2025-corporate-milestones/ 2025-01-28T07:30:00+00:00 https://palatin.com/press_releases/palatin-completes-phase-2-obesity-study-with-mc4r-bremelanotide-plus-glp-1-gip-tirzepatide/ 2025-02-06T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-4-7-million-registered-direct-offering-and-concurrent-private-placement/ 2025-02-07T08:00:00+00:00 https://palatin.com/press_releases/palatin-to-report-second-quarter-fiscal-year-2025-results-teleconference-and-webcast-to-be-held-on-february-13-2025/ 2025-02-10T16:00:00+00:00 https://palatin.com/press_releases/palatin-reports-second-quarter-fiscal-year-2025-financial-results-and-provides-business-update/ 2025-02-13T07:30:00+00:00 https://palatin.com/press_releases/palatins-oral-mc4r-agonist-pl7737-receives-fda-orphan-drug-designation-for-obesity-due-to-leptin-receptor-deficiency/ 2025-03-25T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-positive-topline-results-from-phase-2-ulcerative-colitis-uc-study-of-oral-melanocortin-1-receptor-agonist-pl8177/ 2025-03-28T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1-gip-tirzepatide-meets-primary-endpoint-in-phase-2-obesity-study/ 2025-03-31T07:30:00+00:00 https://palatin.com/press_releases/palatin-to-present-positive-phase-2b-data-for-melanocortin-agonist-in-diabetic-kidney-disease-at-the-national-kidney-foundation-spring-meeting/ 2025-04-10T07:30:00+00:00 https://palatin.com/press_releases/palatin-technologies-inc-announces-receipt-of-nyse-american-notice-of-delisting-and-intention-to-appeal/ 2025-04-10T16:01:00+00:00 https://palatin.com/press_releases/palatin-appeals-nyse-american-notice-of-delisting/ 2025-04-14T07:00:00+00:00 https://palatin.com/press_releases/palatin-reports-positive-appetite-suppression-results-from-phase-2-obesity-study-of-mc4r-agonist-bremelanotide-and-tirzepatide/ 2025-04-17T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-breakthrough-symptom-resolution-in-updated-analyses-from-phase-3-pl9643-melody-1-clinical-trial-in-dry-eye-disease/ 2025-04-29T07:30:00+00:00 https://palatin.com/press_releases/palatin-presents-promising-preclinical-data-for-melanocortin-agonist-pl9588-at-arvo-2025-highlighting-a-dual-action-glaucoma-therapy/ 2025-05-05T07:30:00+00:00 https://palatin.com/press_releases/palatin-technologies-announces-pricing-of-up-to-23-million-public-offering/ 2025-05-07T08:00:00+00:00 https://palatin.com/press_releases/palatin-expects-11-5-million-financing-to-cure-nyse-american-delisting-notice/ 2025-05-07T08:15:00+00:00 https://palatin.com/press_releases/palatin-technologies-announces-transition-to-otc-pink-following-nyse-american-delisting-notice/ 2025-05-07T20:26:00+00:00 https://palatin.com/press_releases/palatin-presents-breakthrough-symptom-resolution-data-from-phase-3-pl9643-melody-1-clinical-trial-in-dry-eye-disease-at-arvo-2025/ 2025-05-08T16:39:00+00:00 https://palatin.com/press_releases/palatin-technologies-announces-closing-of-reduced-public-offering/ 2025-05-08T22:19:00+00:00 https://palatin.com/press_releases/palatin-presents-promising-preclinical-data-on-melanocortin-agonists-for-retinopathy-at-arvo-2025/ 2025-05-09T07:30:00+00:00 https://palatin.com/press_releases/palatin-reports-fiscal-year-2025-third-quarter-results-and-business-update/ 2025-05-14T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-positive-preclinical-efficacy-data-for-oral-mc4r-agonist-pl7737-in-animal-model-of-obesity/ 2025-07-15T07:30:00+00:00 https://palatin.com/press_releases/palatin-announces-1-for-50-reverse-stock-split/ 2025-08-08T16:00:00+00:00 https://palatin.com/press_releases/boehringer-ingelheim-and-palatin-technologies-to-develop-potential-first-in-class-melanocortin-receptor-targeted-treatment-for-patients-with-retinal-diseases/ 2025-08-18T08:52:20+00:00 https://palatin.com/press_releases/palatin-earns-e5-5-million-6-5-million-milestone-payment-in-retinal-disease-collaboration-with-boehringer-ingelheim/ 2025-09-22T07:30:00+00:00 https://palatin.com/press_releases/palatin-technologies-announces-pricing-of-upsized-15-8-million-public-offering/ 2025-11-06T07:30:00+00:00 https://palatin.com/press_releases/palatin-presents-data-at-obesityweek-2025-highlighting-promise-of-melanocortin-based-therapies-for-obesity/ 2025-11-06T08:00:00+00:00 https://palatin.com/press_releases/palatin-technologies-announces-closing-of-upsized-18-2-million-public-offering-with-the-full-exercise-of-the-underwriters-over-allotment-option/ 2025-11-12T12:15:00+00:00 https://palatin.com/press_releases/palatin-reports-first-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update/ 2025-11-13T07:30:00+00:00 https://palatin.com/press_releases/palatin-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update/ 2026-02-17T07:30:00+00:00 https://palatin.com/press_releases/palatin-reports-fiscal-third-quarter-2026-financial-results-and-provides-business-update/ 2026-05-13T07:30:00+00:00 https://palatin.com/press_releases/palatin-to-begin-trading-on-nasdaq-stock-exchange/ 2026-05-18T16:00:00+00:00 https://palatin.com/press_releases/palatin-reports-fiscal-year-2026-financial-results-and-provides-business-update/ 2026-09-28T07:30:00+00:00